Linked Life Data

12449039

Source:http://linkedlifedata.com/resource/pubmed/id/12449039

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2002-11-25
pubmed:abstractText
Among genito-urinary tumors, gemcitabine has only got the marketing approval for advanced urothelial cancer. The combination of gemcitabine and cisplatin has been shown to be a new standard of treatment in this disease because of equal efficacy and lesser toxicity as compared to the classic M-VAC protocol which includes methotrexate, vinblastin, doxorubicin and cisplatin. However new trials are required with the aim of improving survival, especially in the adjuvant setting after cystectomy. The role of gemcitabine in other tumors of the genito-urinary tract has to be determined.
pubmed:language
fre
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:author
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S102-6
pubmed:dateRevised
2009-11-11
pubmed:articleTitle
[Gemcitabine and urogenital tumors].
pubmed:affiliation
CRLC Val-d'Aurelle, parc Euromédecine, 34298 Montpellier. stculine@valdorel.fnclcc.fr